IMELCIMENT

UNII:	T7U2Z3N6QH
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	IMELCIMENT
GSRS Full Record:	T7U2Z3N6QH i

2845128-03-0
H-gamma4 heavy chain anti-vixticibart Homo sapiens (1-448) [VH (Homo sapiens IGHV3-30-5*03 (94.9%) -(IGHD) -IGHJ4*01 (92.9%) T122>I (115), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10, G4v8 CH3 R115, F116, P125 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 L92 (310) (232-341), CH3 H115>R (436), Y116>F (437), L125>P (446) (342-446), CHS (447-448)) (122-448)], (135-213')-disulfide with L-kappa light chain anti-vixticibart Homo imelciment imelciment sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV1-5*03 (98.9%) -IGKJ1*01 (91.7%) Q120>P (99'), CDR-IMGT [6.3.8] (27'-32'.50'-52'.89'-96')) (1'-106') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (152'), V101 (190') (107'-213')]; G4hCH2CH3 chain Homo sapiens (1''-229'') [Homo sapiens IGHG4*01 (100%), nG4m(a) CH2 L92, G4v5 h P10 (hinge 1-12 S10>P (10'') (1''-12''), CH2 L92 (310'') (13''-122''), CH3 (123''-227''), CHS (228''-229''))]; dimer (227-8'':230-11'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1
Imelciment
Immunoglobulin G4 [229-proline,436-arginine,437-phenylalanine,446-proline], anti-(human natriuretic peptide receptor A) (human monoclonal REGN9035 γ4-chain), (227→8′),(230→11′)-bis(disulfide) with immunoglobulin G4 [10′-proline,217′-histidine,218′-tyrosine] (human γ4-chain C region C-terminal fragment), disulfide with human monoclonal REGN9035 κ-chain
REGN-9035
REGN9035
imelciment [INN]
immunoglobulin (H-gamma4_L-kappa)_G4hCH2CH3, anti-[vixticibart,monoclonal antibody allosteric agonist of Homo sapiens NPR1 (atrial natriuretic peptide receptor 1)], Homo sapiens monoclonal antibody

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

IMELCIMENT

Synonyms and Mappings

Resources